外阴阴道假丝酵母菌病的治疗现状与展望

doi:10.12280/gjfckx.20201006

摘要/Abstract

摘要：

外阴阴道假丝酵母菌病（vulvovaginal candidiasis,VVC）是影响妇女生活质量的常见疾病,约有75%的妇女一生中至少会感染一次,每年导致约18亿美元的经济负担。目前临床常用的治疗VVC的药物主要是唑类和多烯类。但随着临床抗真菌药物的长期使用,假丝酵母菌出现表型改变、毒力因子突变、非白色假丝酵母菌的感染增加,对传统抗菌药物的治疗效果提出挑战,急需开发新的有效的抗菌药物。对于VVC的治疗,现阶段处于临床试验阶段的疫苗有PEV7和NDV3,处于实验室研发阶段的药物有益生菌类、抗菌肽类、草本植物类、纳米颗粒类,还有一些药物包括VT-1161、CD101、可溶性β-葡聚糖等也在研究阶段表现出抗真菌效果,有望成为治疗VVC的候选药物。总的来说,VVC发生率高,复发率高,临床上急需新的抗菌药物改善患者生活质量,减少医疗经济负担。

关键词: 念珠菌病,外阴阴道, 白色念珠菌, 抗真菌药, 疫苗, 治疗, 外阴阴道假丝酵母菌病

Abstract:

Vulvovaginal candidiasis (VVC) is a common disease that affects women′s quality of life. About 75% of women will be infected at least once in their lifetime, and VVC causes an economic burden of $1.8 billion each year. At present, treatment of VVC commonly used in clinic mainly includes azoles and polyenes. However, with the long-term use of clinical antifungal drugs, candida phenotype changes, virulence factor mutates, and non-candida infections increase, which pose challenges to the therapeutic effects of traditional antifungal drugs. We urgently need to develop new effective ones. For the treatment of VVC, the vaccines currently in clinical trials include PEV7 and NDV3, the drugs in the laboratory development stage are probiotics, antimicrobial peptides, herbs, nanoparticles, and some drugs include VT-1161, CD101, soluble β-glucan etc. have also shown antifungal effects in the research stage and are expected to be candidate drugs for the treatment of VVC. In general, the incidence and recurrence rate of VVC is high, there is an urgent need for new antibacterial drugs to improve the quality of life of patients and reduce the medical economic burden.

Key words: Candidiasis,vulvovaginal, Candida albicans, Antifungal agents, Vaccines, Therapy, Vulvovaginal candidiasis

张芳芳, 巨宇叶, 田蕾, 王晓慧. 外阴阴道假丝酵母菌病的治疗现状与展望[J]. 国际妇产科学杂志, 2021, 48(4): 425-428.

ZHANG Fang-fang, JU Yu-ye, TIAN Lei, WANG Xiao-hui. Current Remedy Condition and Prospect of Vulvovaginal Candidiasis[J]. Journal of International Obstetrics and Gynecology, 2021, 48(4): 425-428.

参考文献 41

[1]	Lines A, Vardi-Flynn I, Searle C. Recurrent vulvovaginal candidiasis[J]. BMJ, 2020, 369:m1995. doi: 10.1136/bmj.m1995. doi: 10.1136/bmj.m1995
[2]	Willems H, Ahmed SS, Liu J, et al. Vulvovaginal Candidiasis: A Current Understanding and Burning Questions[J]. J Fungi(Basel), 2020, 6(1):27. doi: 10.3390/jof6010027. doi: 10.3390/jof6010027
[3]	De Bernardis F, Graziani S, Tirelli F, et al. Candida vaginitis: virulence, host response and vaccine prospects[J]. Med Mycol, 2018, 56(Suppl 1):26-31. doi: 10.1093/mmy/myx139. doi: 10.1093/mmy/myx139
[4]	Hillier SL, Austin M, Macio I, et al. Diagnosis and Treatment of Vaginal Discharge Syndromes in Community Practice Settings[J]. Clin Infect Dis, 2020 Apr 30:ciaa260. doi: 10.1093/cid/ciaa260. doi: 10.1093/cid/ciaa260
[5]	Ghaddar N, Anastasiadis E, Halimeh R, et al. Prevalence and antifungal susceptibility of Candida albicans causing vaginal discharge among pregnant women in Lebanon[J]. BMC Infect Dis, 2020, 20(1):32. doi: 10.1186/s12879-019-4736-2. doi: 10.1186/s12879-019-4736-2 pmid: 31931738
[6]	Collins LM, Moore R, Sobel JD. Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by Candida albicans[J]. J Low Genit Tract Dis, 2020, 24(1):48-52. doi: 10.1097/LGT.0000000000000496. doi: 10.1097/LGT.0000000000000496
[7]	Shi Y, Zhu Y, Fan S, et al. Clinical Characteristics and Antifungal Susceptibility of Candida nivariensis from Vulvovaginal Candidiasis[J]. Gynecol Obstet Invest, 2020, 85(1):88-93. doi: 10.1159/000504095. doi: 10.1159/000504095
[8]	Feng W, Yang J, Ji Y, et al. Mrr2 mutations and upregulation are associated with increased fluconazole resistance in Candida albicans isolates from patients with vulvovaginal candidiasis[J]. Lett Appl Microbiol, 2020, 70(2):95-101. doi: 10.1111/lam.13248. doi: 10.1111/lam.13248 pmid: 31705810
[9]	Yassin MT, Mostafa AA, Al-Askar AA, et al. In vitro antifungal resistance profile of Candida strains isolated from Saudi women suffering from vulvovaginitis[J]. Eur J Med Res, 2020, 25(1):1. doi: 10.1186/s40001-019-0399-0. doi: 10.1186/s40001-019-0399-0
[10]	Lírio J, Giraldo PC, Amaral RL, et al. Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol[J]. BMJ Open, 2019, 9(5):e027489. doi: 10.1136/bmjopen-2018-027489. doi: 10.1136/bmjopen-2018-027489
[11]	Story K, Sobel R. Fluconazole Prophylaxis in Prevention of Symptomatic Candida Vaginitis[J]. Curr Infect Dis Rep, 2020, 22(1):2. doi: 10.1007/s11908-020-0712-7. doi: 10.1007/s11908-020-0712-7
[12]	Eastment MC, Balkus JE, Richardson BA, et al. Association between Vaginal Bacterial Microbiota and Vaginal Yeast Colonization[J]. J Infect Dis, 2020 Jul 29:jiaa459. doi: 10.1093/infdis/jiaa459. doi: 10.1093/infdis/jiaa459
[13]	Neal CM, Kus LH, Eckert LO, et al. Noncandidal vaginitis: a comprehensive approach to diagnosis and management[J]. Am J Obstet Gynecol, 2020, 222(2):114-122. doi: 10.1016/j.ajog.2019.09.001. doi: 10.1016/j.ajog.2019.09.001
[14]	Zhu Y, Bateman BT, Gray KJ, et al. Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study[J]. BMJ, 2020, 369:m1494. doi: 10.1136/bmj.m1494. doi: 10.1136/bmj.m1494
[15]	Tso G, Reales-Calderon JA, Pavelka N. The Elusive Anti-Candida Vaccine: Lessons From the Past and Opportunities for the Future[J]. Front Immunol, 2018, 9:897. doi: 10.3389/fimmu.2018.00897. doi: 10.3389/fimmu.2018.00897
[16]	Schmidt CS, White CJ, Ibrahim AS, et al. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults[J]. Vaccine, 2012, 30(52):7594-7600. doi: 10.1016/j.vaccine.2012.10.038. doi: 10.1016/j.vaccine.2012.10.038 pmid: 23099329
[17]	De Bernardis F, Amacker M, Arancia S, et al. A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models[J]. Vaccine, 2012, 30(30):4490-4498. doi: 10.1016/j.vaccine.2012.04.069. doi: 10.1016/j.vaccine.2012.04.069 pmid: 22561143
[18]	Gaziano R, Sabbatini S, Roselletti E, et al. Saccharomyces cerevisiae-Based Probiotics as Novel Antimicrobial Agents to Prevent and Treat Vaginal Infections[J]. Front Microbiol, 2020, 11:718. doi: 10.3389/fmicb.2020.00718. doi: 10.3389/fmicb.2020.00718
[19]	van de Wijgert J, Verwijs MC. Lactobacilli-containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs[J]. BJOG, 2020, 127(2):287-299. doi: 10.1111/1471-0528.15870. doi: 10.1111/1471-0528.15870
[20]	Donders G, Bellen G, Oerlemans E, et al. The use of 3 selected lactobacillary strains in vaginal probiotic gel for the treatment of acute Candida vaginitis: a proof-of-concept study[J]. Eur J Clin Microbiol Infect Dis, 2020, 39(8):1551-1558. doi: 10.1007/s10096-020-03868-x. doi: 10.1007/s10096-020-03868-x
[21]	Jin L, Bai X, Luan N, et al. A Designed Tryptophan- and Lysine/Arginine-Rich Antimicrobial Peptide with Therapeutic Potential for Clinical Antibiotic-Resistant Candida albicans Vaginitis[J]. J Med Chem, 2016, 59(5):1791-1799. doi: 10.1021/acs.jmedchem.5b01264. doi: 10.1021/acs.jmedchem.5b01264
[22]	Yassin MT, Mostafa AA, Al-Askar AA. In vitro anticandidal potency of Syzygium aromaticum (clove) extracts against vaginal candidiasis[J]. BMC Complement Med Ther, 2020, 20(1):25. doi: 10.1186/s12906-020-2818-8. doi: 10.1186/s12906-020-2818-8
[23]	Wang Z, Yang K, Chen L, et al. Activities of Nerol, a natural plant active ingredient, against Candida albicans in vitro and in vivo[J]. Appl Microbiol Biotechnol, 2020, 104(11):5039-5052. doi: 10.1007/s00253-020-10559-2. doi: 10.1007/s00253-020-10559-2
[24]	Araújo DE, de Oliveira AA, Cabral M, et al. Investigation of thiosemicarbazide free or within chitosan nanoparticles in a murine model of vulvovaginal candidiasis[J]. Braz J Microbiol, 2020, 51(4):1465-1473. doi: 10.1007/s42770-020-00326-w. doi: 10.1007/s42770-020-00326-w
[25]	Hosseini SS, Joshaghani H, Shokohi T, et al. Antifungal Activity of ZnO Nanoparticles and Nystatin and Downregulation of SAP1-3 Genes Expression in Fluconazole-Resistant Candida albicans Isolates from Vulvovaginal Candidiasis[J]. Infect Drug Resist, 2020, 13:385-394. doi: 10.2147/IDR.S226154. doi: 10.2147/IDR.S226154
[26]	Melo CM, Cardoso JF, Perasoli FB, et al. Data on statistical experimental design to formulate amphotericin B-loaded Eudragit RL100 nanoparticles coated with hyaluronic acid for the treatment of vulvovaginal candidiasis[J]. Data Brief, 2020, 29:105311. doi: 10.1016/j.dib.2020.105311. doi: 10.1016/j.dib.2020.105311
[27]	Song R, Yan F, Cheng M, et al. Ultrasound-Assisted Preparation of Exopolysaccharide/Nystatin Nanoemulsion for Treatment of Vulvovaginal Candidiasis[J]. Int J Nanomedicine, 2020, 15:2027-2044. doi: 10.2147/IJN.S241134. doi: 10.2147/IJN.S241134
[28]	Sobel JD, Sobel R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species[J]. Expert Opin Pharmacother, 2018, 19(9):971-977. doi: 10.1080/14656566.2018.1476490. doi: 10.1080/14656566.2018.1476490 pmid: 29932786
[29]	Schell WA, Jones AM, Garvey EP, et al. Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds[J]. Antimicrob Agents Chemother, 2017, 61(3):e01817-16. doi: 10.1128/AAC.01817-16. doi: 10.1128/AAC.01817-16
[30]	Garvey EP, Hoekstra WJ, Schotzinger RJ, et al. Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis[J]. Antimicrob Agents Chemother, 2015, 59(9):5567-5573. doi: 10.1128/AAC.00185-15. doi: 10.1128/AAC.00185-15 pmid: 26124165
[31]	Jiménez-Ortigosa C, Paderu P, Motyl MR, et al. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates[J]. Antimicrob Agents Chemother, 2014, 58(2):1248-1251. doi: 10.1128/AAC.02145-13. doi: 10.1128/AAC.02145-13 pmid: 24323472
[32]	Lepak AJ, Marchillo K, Andes DR. Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model[J]. Antimicrob Agents Chemother, 2015, 59(2):1265-1272. doi: 10.1128/AAC.04445-14. doi: 10.1128/AAC.04445-14
[33]	Shi Y, Zhu Y, Fan S, et al. Molecular identification and antifungal susceptibility profile of yeast from vulvovaginal candidiasis[J]. BMC Infect Dis, 2020, 20(1):287. doi: 10.1186/s12879-020-04985-w. doi: 10.1186/s12879-020-04985-w pmid: 32393342
[34]	Nyirjesy P, Alessio C, Jandourek A, et al. CD101 Topical Compared With Oral Fluconazole for Acute Vulvovaginal Candidiasis: A Randomized Controlled Trial[J]. J Low Genit Tract Dis, 2019, 23(3):226-229. doi: 10.1097/LGT.0000000000000473. doi: 10.1097/LGT.0000000000000473
[35]	Wang T, Dong J, Yin H, et al. Blue light therapy to treat candida vaginitis with comparisons of three wavelengths: an in vitro study[J]. Lasers Med Sci, 2020, 35(6):1329-1339. doi: 10.1007/s10103-019-02928-9. doi: 10.1007/s10103-019-02928-9
[36]	夏艳, 金志军. 外阴阴道假丝酵母菌病治疗的研究进展[J]. 国际妇产科学杂志, 2011, 38(2):101-104,111. doi: 10.3969/j.issn.1674-1870.2011.02.005. doi: 10.3969/j.issn.1674-1870.2011.02.005
[37]	Shukla A, Sobel JD. Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure[J]. Curr Infect Dis Rep, 2019, 21(11):44. doi: 10.1007/s11908-019-0700-y. doi: 10.1007/s11908-019-0700-y
[38]	Shenoy A, Gottlieb A. Probiotics for oral and vulvovaginal candidiasis: A review[J]. Dermatol Ther, 2019, 32(4):e12970. doi: 10.1111/dth.12970. doi: 10.1111/dth.12970
[39]	Donders GG, Grinceviciene S, Ruban K, et al. Vaginal pH and microbiota during fluconazole maintenance treatment for recurrent vulvovaginal candidosis (RVVC)[J]. Diagn Microbiol Infect Dis, 2020, 97(2):115024. doi: 10.1016/j.diagmicrobio.2020.115024. doi: 10.1016/j.diagmicrobio.2020.115024
[40]	许玲, 林小能, 胡正强. 14~18岁青春发育晚期女性的生殖道感染特征[J]. 国际生殖健康/计划生育杂志, 2020, 39(2):121-125. doi: 10.3969/j.issn.1674-1889.2020.02.008. doi: 10.3969/j.issn.1674-1889.2020.02.008
[41]	肖彩艳, 张洪文, 王新, 等. 2066例妇女阴道微生态失调构成情况分析[J]. 国际妇产科学杂志, 2012, 39(2):191-193. doi: 10.3969/j.issn.1674-1870.2012.02.021. doi: 10.3969/j.issn.1674-1870.2012.02.021